446 related articles for article (PubMed ID: 17655372)
1. Clinical pharmacokinetics and use of infliximab.
Klotz U; Teml A; Schwab M
Clin Pharmacokinet; 2007; 46(8):645-60. PubMed ID: 17655372
[TBL] [Abstract][Full Text] [Related]
2. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
Keating GM; Perry CM
BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
[TBL] [Abstract][Full Text] [Related]
3. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
4. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
Siddiqui MA; Scott LJ
Drugs; 2005; 65(15):2179-208. PubMed ID: 16225377
[TBL] [Abstract][Full Text] [Related]
5. Infliximab treatment of rheumatoid arthritis and Crohn's disease.
Nahar IK; Shojania K; Marra CA; Alamgir AH; Anis AH
Ann Pharmacother; 2003 Sep; 37(9):1256-65. PubMed ID: 12921510
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
[TBL] [Abstract][Full Text] [Related]
7. A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy.
Mori S
Mod Rheumatol; 2007; 17(2):83-91. PubMed ID: 17437161
[TBL] [Abstract][Full Text] [Related]
8. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE).
Bondeson J; Maini RN
Int J Clin Pract; 2001 Apr; 55(3):211-6. PubMed ID: 11351775
[TBL] [Abstract][Full Text] [Related]
9. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease.
Han PD; Cohen RD
Drugs; 2004; 64(16):1767-77. PubMed ID: 15301561
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on infliximab in Crohn disease and rheumatoid arthritis.
Siddiqui MA; Scott LJ
BioDrugs; 2006; 20(1):67-70. PubMed ID: 16573354
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological profile of anti-human TNF alpha monoclonal antibody, infliximab (Remicade)].
Sugita T
Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):57-64. PubMed ID: 12617039
[TBL] [Abstract][Full Text] [Related]
12. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
Onrust SV; Lamb HM
BioDrugs; 1998 Nov; 10(5):397-422. PubMed ID: 18020611
[TBL] [Abstract][Full Text] [Related]
13. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
14. [Targeting therapy for inflammatory diseases by anti-TNFalpha biologics].
Sugita T
Yakugaku Zasshi; 2009 Jan; 129(1):19-24. PubMed ID: 19122432
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
Rutgeerts P; D'Haens G; Targan S; Vasiliauskas E; Hanauer SB; Present DH; Mayer L; Van Hogezand RA; Braakman T; DeWoody KL; Schaible TF; Van Deventer SJ
Gastroenterology; 1999 Oct; 117(4):761-9. PubMed ID: 10500056
[TBL] [Abstract][Full Text] [Related]
16. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
[TBL] [Abstract][Full Text] [Related]
17. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
[TBL] [Abstract][Full Text] [Related]
18. Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model.
Ternant D; Pfister M; Le Tilly O; Mulleman D; Picon L; Willot S; Passot C; Bejan-Angoulvant T; Lecomte T; Paintaud G; Koch G
Clin Pharmacokinet; 2022 Jan; 61(1):143-154. PubMed ID: 34351609
[TBL] [Abstract][Full Text] [Related]
19. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
Maser EA; Villela R; Silverberg MS; Greenberg GR
Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
[TBL] [Abstract][Full Text] [Related]
20. The underlying inflammatory chronic disease influences infliximab pharmacokinetics.
Passot C; Mulleman D; Bejan-Angoulvant T; Aubourg A; Willot S; Lecomte T; Picon L; Goupille P; Paintaud G; Ternant D
MAbs; 2016 Oct; 8(7):1407-1416. PubMed ID: 27589009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
